About ev3 Endovascular
ev3 Endovascular is a company based in Plymouth (United States) founded in 2000 was acquired by Covidien in June 2010. ev3 Endovascular has raised $58.8 million across 1 funding round from investors including Warburg Pincus, Covidien and The Vertical Group. The company has 1,307 employees as of December 31, 2009. ev3 Endovascular has completed 3 acquisitions, including Chestnut Medical, EndiCor Medical and FoxHollow Technologies. ev3 Endovascular operates in a competitive market with competitors including Contego Medical, Echopoint Medical, Limflow, AngioScore and Vascular Solutions, among others.
- Headquarter Plymouth, United States
- Employees 1307 as on 31 Dec, 2009
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ev3 Endovascular, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$58.8 M (USD)
in 1 rounds
-
Latest Funding Round
$58.8 M (USD), Series A
Jun 01, 2002
-
Investors
Warburg Pincus
& 2 more
-
Employee Count
1307
as on Dec 31, 2009
-
Investments & Acquisitions
Chestnut Medical
& 2 more
-
Acquired by
Covidien
(Jun 01, 2010)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of ev3 Endovascular
ev3 Endovascular has successfully raised a total of $58.8M through 1 strategic funding round. The most recent funding activity was a Series A round of $58.8 million completed in June 2002. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ev3 Endovascular
ev3 Endovascular has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Warburg Pincus, Covidien and The Vertical Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in early and late-stage US companies are made.
|
Locked | Locked | Locked | |
|
Multi-stage private equity investments are pursued across diverse sectors.
|
Locked | Locked | Locked | |
|
Medical devices for minimally invasive therapies are provided globally.
|
Locked | Locked | Locked |
Investor details for ev3 Endovascular
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ev3 Endovascular
ev3 Endovascular has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Chestnut Medical, EndiCor Medical and FoxHollow Technologies.
Investment portfolio details for ev3 Endovascular
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Minimally invasive therapies for interventional neuroradiology are developed and provided.
|
Locked | Locked | 2003 | Locked | |
|
Medical devices for the treatment of coronary and peripheral arterial disease
|
Locked | Locked | 1996 | Locked | |
|
Medical devices for cardiovascular treatments are developed.
|
Locked | Locked | 1995 | Locked |
Complete acquisition details for ev3 Endovascular
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - ev3 Endovascular
Detailed financials for ev3 Endovascular
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ev3 Endovascular Comparisons
Peer comparison for ev3 Endovascular
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ev3 Endovascular
ev3 Endovascular operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Contego Medical, Echopoint Medical, Limflow, AngioScore and Vascular Solutions, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of vascular stenting with embolic protection for both coronary and peripheral vasculature
|
|
| Locked | Locked | Locked |
Smart devices for monitoring coronary artery disease are developed.
|
|
| Locked | Locked | Locked |
Developer a system for venous arterialization of the lower limbs
|
|
| Locked | Locked | Locked |
Scoring balloon catheters for coronary and peripheral angioplasty are developed.
|
|
| Locked | Locked | Locked |
Products for vascular diagnostics and interventional procedures are developed.
|
|
| Locked | Locked | Locked |
Devices for treating peripheral and coronary vascular disease are developed.
|
Detailed competitors of ev3 Endovascular
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ev3 Endovascular
Complete news archive for ev3 Endovascular
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ev3 Endovascular
ev3 Endovascular was founded in 2000 and raised its 1st funding round 2 years after it was founded.
ev3 Endovascular is headquartered in Plymouth, United States. It is registered at Plymouth, Massachusetts, United States.
Bob Palmisano is the current CEO of ev3 Endovascular.
ev3 Endovascular is a funded company, having raised a total of $58.8M across 1 funding round to date.
As of Dec 31, 2009, the latest employee count at ev3 Endovascular is 1,307.
ev3 Endovascular (previously known as Vertomed) develops, manufactures, and commercializes equipment, technologies, and solutions for the treatment of peripheral vascular and neurovascular diseases. Its products include plaque excision systems, stents, carotid stents, percutaneous transluminal angioplasty balloons, embolic protection devices, thrombus management systems, blood clot therapy products, procedural support products, embolization coils, liquid embolics, micro catheters, thrombectomy catheters, occlusion balloons, guidewires, and retrieval devices. The company sells more than 100 products in more than 65 countries through a direct sales team and distributors. Among its customers are radiologists, cardiologists, neurosurgeons, and vascular surgeons. The company sells its products in Asia Pacific, Latin America, Eastern Europe, and the Middle East. eV3 endovascular was acquired by Covidien in 2010 for 2.6 Billion. Before beinmg acquired by Covidien, eV3 had acquired Endicor Medical, Microvena, Mitralife, Appriva Medical, Intratherapeutics.
ev3 Endovascular's top competitors include Contego Medical, Limflow and Shape Memory Medical.
ev3 Endovascular has made 3 acquisitions, including Chestnut Medical, EndiCor Medical, and FoxHollow Technologies.
ev3 Endovascular has 3 investors. Key investors include Warburg Pincus, Covidien, and The Vertical Group.